PDS Biotechnology Corporation (PDSB)

$ 10.31
+0.66 (+6.84%)
-
Symbol PDSB
Price $ 10.31
Beta 1.769
Volume Avg. 0.45M
Market Cap 0.293B
Shares () -
52 Week Range 1.94-17.85
1y Target Est -
DCF Unlevered PDSB DCF ->
DCF Levered PDSB LDCF ->
ROE -30.41% Strong Sell
ROA -20.38% Sell
Operating Margin -
Debt / Equity 5.73% Neutral
P/E -
P/B 4.32 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest PDSB news


Dr. Frank Bedu-Addo
Healthcare
Biotechnology
Nasdaq Global Select

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Princeton, New Jersey and currently employs 14 full-time employees. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.